<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03018366</url>
  </required_header>
  <id_info>
    <org_study_id>PRO26081</org_study_id>
    <nct_id>NCT03018366</nct_id>
  </id_info>
  <brief_title>Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women</brief_title>
  <official_title>Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether low estrogen levels in young women with&#xD;
      hypothalamic amenorrhea (premenopausal HypoE) is associated with risk factors for&#xD;
      cardiovascular disease.&#xD;
&#xD;
      For this study, the investigators will measuring vascular function and immune markers on:&#xD;
&#xD;
        -  young women with hypothalamic amenorrhea (&gt;3 months of no menstrual cycle due to low&#xD;
           estrogen)&#xD;
&#xD;
        -  young women with regular menstrual cycles not on hormone therapy.&#xD;
&#xD;
        -  recently menopausal women (&lt;3 years from final menstrual period) not on hormone therapy.&#xD;
&#xD;
      Premenopausal HypoE participants will then be randomized to use either an estrogen patch or a&#xD;
      placebo patch (no active medicine) for 3 months, followed by estrogen or placebo patch plus&#xD;
      progesterone or placebo pills for 2 additional weeks. The investigators are looking to see if&#xD;
      estrogen improves vascular and immune function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Aims:&#xD;
&#xD;
        1. To test the hypothesis premenopausal HypoE is associated with pre-clinical CVD as&#xD;
           determined by reductions in vascular endothelial function and increased central arterial&#xD;
           stiffness.&#xD;
&#xD;
        2. To test the hypothesis premenopausal HypoE is associated with increased immune-mediated&#xD;
           inflammation.&#xD;
&#xD;
        3. To test the hypothesis estrogens can reduce inflammation, improve vascular endothelial&#xD;
           function and central arterial stiffness in premenopausal HypoE women.&#xD;
&#xD;
      In a randomized, double-blind placebo-controlled trial in premenopausal HypoE women the&#xD;
      investigators will test 12 weeks of transdermal estradiol 0.1 mg/day patch or placebo&#xD;
      followed by 2 weeks of estradiol plus progesterone 200mg on vascular endothelial function,&#xD;
      arterial stiffness and immune-mediated inflammation versus placebo. Patches will be applied&#xD;
      by the participant to the lower abdomen twice weekly, alternating sides.&#xD;
&#xD;
      The investigators will be using non-invasive tests to measure vascular function including:&#xD;
&#xD;
        -  Peripheral arterial tonometry (PAT)&#xD;
&#xD;
        -  SphygmoCor measurements of central blood pressure&#xD;
&#xD;
        -  Carotid intima-media thickness (CIMT)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of change of peripheral arterial tonometry (PAT)</measure>
    <time_frame>Baseline, week 6, 12, and 14 on trial</time_frame>
    <description>PAT measured as reactive hyperemia index (RHI%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of change of pulse wave analysis</measure>
    <time_frame>Baseline, week 6, 12, and 14 on trial</time_frame>
    <description>SphymoCor measured as augmentation index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change of pulse wave velocity</measure>
    <time_frame>Baseline, week 6, 12, and 14 on trial</time_frame>
    <description>SphymoCor measured as meters/second</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change of distal common carotid artery, Carotid Intima-Media Thickness (cIMT)</measure>
    <time_frame>Baseline, week 6, 12, and 14 on trial</time_frame>
    <description>Measurement of distal common carotid artery in millimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Inflammatory Markers</measure>
    <time_frame>Baseline, week 6, 12, and 14 on trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormone levels</measure>
    <time_frame>Baseline, week 6, 12, and 14 on trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (questionnaire)</measure>
    <time_frame>Baseline, week 6, 12, and 14 on trial</time_frame>
    <description>Short-Form Health Survey 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>Baseline, week 6, 12, and 14 on trial</time_frame>
    <description>Patient Health Questionnaire (PHQ-9)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep changes</measure>
    <time_frame>Baseline, week 6, 12, and 14 on trial</time_frame>
    <description>Insomnia Severity Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>Baseline, week 6, 12, and 14 on trial</time_frame>
    <description>Overall Anxiety Severity and Impairment Scale (OASIS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress</measure>
    <time_frame>Baseline, week 6, 12, and 14 on trial</time_frame>
    <description>Cohen Perceived Stress Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DEXA Scan</measure>
    <time_frame>Baseline</time_frame>
    <description>dual-energy x-ray absorptiometry (DEXA) bone mass</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Estrogen Deficiency</condition>
  <condition>Cardiovascular Disease (CVD)</condition>
  <condition>Hypothalamic Amenorrhea</condition>
  <arm_group>
    <arm_group_label>17Beta Estradiol, Progesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>17Beta Estradiol (0.1mg/day) , Progesterone (200mg) or Medroxyprogesterone (10mg) for patient with a peanut allergy because progesterone 200mg is a peanut based product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transdermal Placebo Patch, Placebo Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Transdermal Patch, Placebo Pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>17beta Estradiol</intervention_name>
    <description>Participants will use a dose of transdermal estradiol 0.1 mg/day patch for 12 weeks +/- 1week. PAT index and sphygmoCor vascular measures and serum immune markers will be measured after 6 and 12 weeks +/- 1week on estrogen patches. Patches will be applied by the participant to the lower abdomen twice weekly, alternating sides.</description>
    <arm_group_label>17Beta Estradiol, Progesterone</arm_group_label>
    <other_name>Estradiol Transdermal Patch</other_name>
    <other_name>Vivelle-Dot</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal placebo patch</intervention_name>
    <description>Participants will use a dose of placebo patches for 12 weeks +/- 1 week. Placebos will be applied by the participant to the lower abdomen twice weekly, alternating sides.</description>
    <arm_group_label>Transdermal Placebo Patch, Placebo Pill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>After 12 weeks +/- 1week of transdermal estradiol patch, participants will use estrogen patch plus progesterone for 2 additional weeks +/- 3 days. Progesterone 200mg is a peanut based product and for patients with a peanut allergy we will replace this with a synthetic progestin at an equivalent dose, medroxyprogesterone 10mg.</description>
    <arm_group_label>17Beta Estradiol, Progesterone</arm_group_label>
    <other_name>Prometrium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Pill</intervention_name>
    <description>After 12 weeks +/- 1week of transdermal placebo patch, participants will use placebo patch plus placebo pill for 2 additional weeks +/- 3 days.</description>
    <arm_group_label>Transdermal Placebo Patch, Placebo Pill</arm_group_label>
    <other_name>Placebo Oral Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For premenopausal Hypo E and normal control women inclusions include:&#xD;
&#xD;
          -  Premenopausal currently not on hormone therapy,&#xD;
&#xD;
          -  English speaking (for the purposes of complete psychosocial assessment)&#xD;
&#xD;
          -  able to give informed consent&#xD;
&#xD;
          -  a gynecological age (age since menarche) &gt; 10 and &lt; 25 years, and chronological age &gt;&#xD;
             18 years&#xD;
&#xD;
          -  Within 90-110% of ideal body weight as determined by the 1983 Metropolitan height and&#xD;
             weight table for women&#xD;
&#xD;
          -  All participants with hypothalamic amenorrhea will be diagnosed based on exclusion of&#xD;
             other etiologies for their amenorrhea, including pregnancy, thyroid dysfunction,&#xD;
             hyperprolactinemia, premature ovarian insufficiency, and polycystic ovary disease&#xD;
&#xD;
        For recently menopausal women inclusions include:&#xD;
&#xD;
          -  Follicle stimulating hormones (FSH) &gt;30 and 12 months of amenorrhea,92 within 3 years&#xD;
             of final menstrual period with natural menopausal not on hormone therapy&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
          -  Within 90-110% of ideal body weight&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For premenopausal Hypo E and normal control women exclusions include:&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Hypertension&#xD;
&#xD;
          -  Hyperlipidemia&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Medications including psychotropic or illicit drugs, medical, neurological&#xD;
&#xD;
          -  Ophthalmologic disease except acuity problems&#xD;
&#xD;
          -  Major Axis I disorder other than depression&#xD;
&#xD;
          -  Pregnancy in the last 12 months and/or lactating in the last 6 months&#xD;
&#xD;
          -  Current use of hormone contraceptive or any estrogen or progestin therapy&#xD;
&#xD;
        For HypoE women, exclusion criteria include:&#xD;
&#xD;
        - Allergy to adhesive or tape&#xD;
&#xD;
        For recently menopausal women exclusions also include:&#xD;
&#xD;
          -  Previous or current use of hormone therapy, estrogen or progestin&#xD;
&#xD;
          -  Surgical or chemotherapy induced menopause&#xD;
&#xD;
          -  Premature ovarian failure&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chrisandra Shufelt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Noel Bairey-Merz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shivani Dhawan, MS</last_name>
    <phone>310-248-6602</phone>
    <email>shivani.dhawan@cshs.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole Tovar</last_name>
    <phone>310-423-9666</phone>
    <email>nicole.tovar@cshs.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Barbra Streisand Women's Heart Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shivani Dhawan, MS</last_name>
      <phone>310-248-6602</phone>
      <email>shivani.dhawan@cshs.org</email>
    </contact>
    <contact_backup>
      <last_name>Nicole Tovar</last_name>
      <phone>310-423-9666</phone>
      <email>nicole.tovar@cshs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Chrisandra Shufelt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 1, 2016</study_first_submitted>
  <study_first_submitted_qc>January 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2017</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Chrisandra Shufelt</investigator_full_name>
    <investigator_title>Associate Director, Barbra Streisand Women's Heart Center</investigator_title>
  </responsible_party>
  <keyword>estrogen</keyword>
  <keyword>premenopause</keyword>
  <keyword>menopause</keyword>
  <keyword>amenorrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Amenorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

